Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rintatolimod, IFNα2b, Celecoxib, and Pembrolizumab in Metastatic Triple Negative Breast Cancer
NCT05756166Phase 2Terminated
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Feb 2024
- Primary completion
- Apr 2025
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of rintatolimod, interferon alfa-2b in triple-negative breast cancer (TNBC), sponsored by Roswell Park Comprehensive Cancer Center. Started Feb 2024; status: terminated.
02
Drugs
rintatolimodinterferon alfa-2b
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05756166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05756166.